HK1200530A1 - Predicting tumor response to anti-erbb3 antibodies erbb3 - Google Patents

Predicting tumor response to anti-erbb3 antibodies erbb3

Info

Publication number
HK1200530A1
HK1200530A1 HK15100823.6A HK15100823A HK1200530A1 HK 1200530 A1 HK1200530 A1 HK 1200530A1 HK 15100823 A HK15100823 A HK 15100823A HK 1200530 A1 HK1200530 A1 HK 1200530A1
Authority
HK
Hong Kong
Prior art keywords
erbb3
tumor response
antibodies
predicting tumor
predicting
Prior art date
Application number
HK15100823.6A
Other languages
English (en)
Chinese (zh)
Inventor
Sylvie Vincent
Kristan Meetze
Bin Feng
Steven Tyler
Steve Bottega
Richard Nicoletti
Donna Mcintosh
Jeno Gyuris
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47071464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1200530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of HK1200530A1 publication Critical patent/HK1200530A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
HK15100823.6A 2011-10-06 2015-01-23 Predicting tumor response to anti-erbb3 antibodies erbb3 HK1200530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544206P 2011-10-06 2011-10-06
US201261636183P 2012-04-20 2012-04-20
PCT/US2012/058871 WO2013052745A1 (en) 2011-10-06 2012-10-05 Predicting tumor response to anti-erbb3 antibodies

Publications (1)

Publication Number Publication Date
HK1200530A1 true HK1200530A1 (en) 2015-08-07

Family

ID=47071464

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100823.6A HK1200530A1 (en) 2011-10-06 2015-01-23 Predicting tumor response to anti-erbb3 antibodies erbb3

Country Status (8)

Country Link
US (2) US9828635B2 (ja)
EP (2) EP3974832A1 (ja)
JP (3) JP6169085B2 (ja)
CN (2) CN103959065B (ja)
AU (2) AU2012318541B2 (ja)
CA (1) CA2851314A1 (ja)
HK (1) HK1200530A1 (ja)
WO (1) WO2013052745A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048804A2 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Co., Ltd. Protein biomarker and uses thereof
KR20160086326A (ko) 2013-09-30 2016-07-19 다이이찌 산쿄 가부시키가이샤 핵산 바이오마커 및 이의 용도
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
BR112016020009A2 (pt) 2014-04-10 2017-10-17 Obi Pharma Inc anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
US20180171027A1 (en) * 2015-04-17 2018-06-21 Celldex Therapeutics, Inc. Biomarkers Related to Treatment of Cancer with HER3 and EGFR Inhibitors
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
SG11201908744PA (en) * 2017-03-23 2019-10-30 Univ Pennsylvania Anti-c5a antibodies and uses thereof
KR101927732B1 (ko) 2017-05-31 2018-12-11 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체를 포함하는 항암제 내성 암의 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
CN113684275B (zh) * 2017-06-22 2024-02-27 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
US20210246223A1 (en) * 2018-06-22 2021-08-12 Crd Pharmaceuticals Inc ANTI-HER3 Antibody and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
AU7042994A (en) 1993-05-21 1994-12-20 Amgen, Inc. Recombinant (neu) differentiation factors
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
ES2274537T5 (es) 1996-03-27 2015-09-14 Genentech, Inc. Anticuerpos ErbB3
WO1999014323A1 (en) 1997-09-17 1999-03-25 Urs Eppenberger Heregulin-gamma
US20050208527A1 (en) * 2000-02-28 2005-09-22 Decode Genetics Ehf. Human schizophrenia gene
WO2002046467A2 (en) 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CA2490758C (en) * 2002-07-15 2014-09-23 Genentech, Inc. Dosage form of recombinant humanized monoclonal antibody 2c4
CN1835768A (zh) 2002-07-15 2006-09-20 健泰科生物技术公司 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
US20050095634A1 (en) 2003-10-16 2005-05-05 Genomic Health Inc. qRT-PCR assay system for gene expression profiling
US7444406B2 (en) * 2003-11-13 2008-10-28 At&T Intellectual Property, I.L.P. Method, system, and storage medium for validating users of communications services and messages transmitted
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US20090061422A1 (en) * 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
US20110070247A1 (en) 2007-08-24 2011-03-24 Novartis Ag Protein modulators
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
WO2010127181A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
MX336091B (es) 2009-08-21 2016-01-08 Merrimack Pharmaceuticals Inc Anticuerpos contra el extodominio de erbb3 y usos de los mismos.
JP2013507378A (ja) 2009-10-09 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
KR20120098911A (ko) 2009-12-22 2012-09-05 로슈 글리카트 아게 항-ｈｅｒ3 항체 및 이의 용도
EP2859893A1 (en) * 2010-03-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
JP5858984B2 (ja) 2010-04-18 2016-02-10 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ＥｒｂＢ／ＥｒｂＢリガンドに関連する疾患を治療するための分子及びその分子を使用する方法
AU2011349101A1 (en) 2010-12-24 2013-05-02 Map Diagnostics Pty Ltd Selective reaction monitoring (SRM) derived protein profiles for cancer and other pathologic entities
US20150231238A1 (en) * 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
CA2847525A1 (en) 2011-09-12 2013-03-21 Universiteit Gent Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療

Also Published As

Publication number Publication date
AU2018204889B2 (en) 2021-03-04
EP3974832A1 (en) 2022-03-30
CN103959065B (zh) 2018-07-17
JP2018113987A (ja) 2018-07-26
CN103959065A (zh) 2014-07-30
EP2764364B1 (en) 2021-08-18
US20140242597A1 (en) 2014-08-28
WO2013052745A1 (en) 2013-04-11
JP6169085B2 (ja) 2017-07-26
CN108753942A (zh) 2018-11-06
US20180195120A1 (en) 2018-07-12
AU2012318541B2 (en) 2018-04-12
JP2015501142A (ja) 2015-01-15
JP2017070314A (ja) 2017-04-13
US9828635B2 (en) 2017-11-28
EP2764364A1 (en) 2014-08-13
JP6592468B2 (ja) 2019-10-16
CA2851314A1 (en) 2013-04-11
AU2018204889A1 (en) 2018-07-26
AU2012318541A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
HUS2400016I1 (hu) FCRN elleni antitestek
HK1200530A1 (en) Predicting tumor response to anti-erbb3 antibodies erbb3
IL251697A0 (en) Antibodies against 3erbb and their uses
IL264558A (en) Anti–il–23p19 antibodies
HK1178184A1 (zh) 抗體
EP2722343A4 (en) ANTI-ERBB3 ANTIBODIES
HK1203517A1 (en) Multispecific antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
EP2844290A4 (en) NOVEL ANTIBODIES
HK1210186A1 (en) Anti-h7cr antibodies h7cr
PL2935330T3 (pl) Przeciwciała przeciw notch3
EP2804876A4 (en) NEW ANTIBODIES
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies